8-K/A: Salarius Amends Decoy Merger Terms, Updates Pro Forma Financials

Salarius Pharmaceuticals filed an amendment to its merger agreement with Decoy Therapeutics, correcting pro forma financials and detailing revised ownership and financing terms.

Summary

• Amendment No. 1 to the Form 8-K corrects an immaterial mathematical error in the unaudited pro forma consolidated combined financial information for Salarius Pharmaceuticals, Inc. and Decoy Therapeutics Inc. as of June 30, 2025, and December 31, 2024.
• Salarius is merging with Decoy Therapeutics Inc. in a stock-for-stock transaction, with Decoy surviving as a wholly-owned subsidiary and being the accounting acquirer.
• The merger closing is conditioned upon a Qualified Financing of at least $6.0 million, with Salarius offering an estimated 1,470,588 shares of common stock and warrants for expected proceeds of $8.0 million.
• A 1-for-15 reverse stock split was executed by Salarius on August 15, 2025, to regain Nasdaq compliance.
• Due to significant deterioration in Salarius's stock price, its relative valuation in the merger was reduced from $4.6 million to $2.31 million (Amendment No. 2).
• This reduction changed the relative ownership percentages, with Salarius legacy stockholders retaining 7.6% and Decoy legacy stockholders retaining 92.4% of the combined company, calculated on a fully-diluted basis and before the dilutive effects of the Qualified Financing.
• Amendment No. 4 modified Preferred Stock conversion terms, removing the $2 million threshold for anti-dilution adjustments, changing the calculation to actual per-share offering price, and eliminating the one-year limitation on adjustments.
• The acquired IPR&D asset of $2.151 million from Salarius will be expensed immediately post-merger due to having no alternative future use.

Sentiment

Score: 3

Explanation: The significant reduction in Salarius's valuation and the substantial dilution for its legacy stockholders, coupled with the immediate expensing of its primary pipeline asset, indicate a highly unfavorable outcome for existing Salarius investors. While the merger proceeds with financing, the terms reflect a distressed situation for Salarius.

Positives

• Secured expected proceeds of $8.0 million from the Qualified Financing, exceeding the $6.0 million minimum condition for the merger.
• The reverse stock split on August 15, 2025, aims to regain compliance with Nasdaq minimum bid price requirements.
• Amendment No. 2 introduced post-closing anti-dilution price protection for Preferred Stockholders for subsequent dilutive financings.
• Amendment No. 4 further strengthened anti-dilution protection by removing the $2 million threshold, changing the adjustment calculation to the actual offering price, and eliminating the one-year limitation.
• A majority of Decoy's outstanding debt will be exchanged for Series A & B Preferred Stock, reducing immediate cash obligations for the combined entity.

Negatives

• Salarius's relative valuation in the merger was significantly reduced from $4.6 million to $2.31 million due to substantial deterioration in its common stock price.
• Salarius legacy stockholders' ownership percentage in the combined company was significantly diluted from 14.1% to 7.6% (pre-Qualified Financing dilution).
• The acquired IPR&D asset of $2.151 million from Salarius will be expensed immediately following the merger closing, indicating a lack of direct future utility for Salarius's pipeline asset within the combined entity.
• Pro forma combined operating loss for the six months ended June 30, 2025, was $(4,186) thousand, and for the year ended December 31, 2024, was $(10,381) thousand.
• Pro forma combined net loss for the six months ended June 30, 2025, was $(4,156) thousand, and for the year ended December 31, 2024, was $(11,605) thousand.

Risks

• Merger Closing is conditioned upon achieving minimum proceeds of at least $6.0 million from the Qualified Financing.
• Preferred Stock conversion is contingent upon the combined company meeting Nasdaq initial listing standards and obtaining stockholder approval pursuant to Nasdaq listing rule 5635.
• Pro forma adjustments are preliminary and subject to further revision, with potential material impact on future results and financial position.
• The determination that Decoy is not a variable interest entity is a preliminary expectation and subject to change based on actual equity at risk at Merger Closing.
• Significant costs may be incurred in integrating the operations of Salarius and Decoy, which are not reflected in the pro forma financials.
• Actual results reported post-merger may differ significantly from the unaudited pro forma consolidated combined financial information due to differing assumptions.
• The IPR&D asset acquired from Salarius will be expensed immediately, indicating a risk that Salarius's existing pipeline asset SP-3164 may not generate future value for the combined entity.

Future Outlook

The combined company expects Decoy's senior management to hold key positions and Decoy to designate a majority of the board of directors. The issuance of shares underlying the Preferred Stock is intended to be registered within 60 days of the Merger Closing. The Preferred Stock will not be convertible until the combined company meets Nasdaq initial listing standards and obtains stockholder approval.

Management Comments

• "Decoy has indicated it believes it could incorporate SP-3164 into its platform technology."
• "The respective ownership percentages were the result of arms length negotiations between the management team of Salarius and the management team of Decoy, along with their respective advisors and under the direction of each company's board of directors."

Industry Context

NA

Management Changes

Corporate Governance

Related Party Transactions

• Approximately $140,000 of notes held by Decoy's founders or principals (Rick Pierce, Barbara Hibner, and Peter Marschel) will remain outstanding and will not be repaid with proceeds from the Qualified Financing. These notes have maturity dates extending 12 months beyond the Merger Closing.

Stakeholder Impact

• Shareholders (Salarius Legacy): Face significant dilution, with their ownership percentage reduced from 14.1% to 7.6% (pre-Qualified Financing). The value of their existing IPR&D asset is being expensed.
• Shareholders (Decoy Legacy): Will hold a substantial majority (92.4% pre-Qualified Financing) of the combined company and will designate a majority of the board of directors, indicating a favorable outcome for their control and equity stake.
• Decoy Noteholders: Will exchange a majority of their outstanding debt for Series A & B Preferred Stock, which includes anti-dilution protection and specific redemption/conversion provisions, providing a pathway to equity.
• Management (Decoy): Expected to hold key senior management positions in the combined organization.
• Nasdaq: The combined company must meet initial listing standards and obtain stockholder approval for Preferred Stock conversion to maintain compliance.

Next Steps

• Complete the Qualified Financing to meet the minimum proceeds condition of $6.0 million for merger closing.
• Merger Closing, which will involve First Merger Sub merging into Decoy, followed by Decoy merging into Second Merger Sub.
• Obtain stockholder approval for the conversion of Series A and Series B Preferred Stock.
• Ensure the combined company meets Nasdaq initial listing standards for Preferred Stock conversion.
• Register the issuance of Salarius common stock underlying the Preferred Stock within 60 days of the Merger Closing.
• Conduct a final review of Salarius's accounting policies to conform to Decoy's policies post-merger.

Key Dates

Recommendation

The filing reveals a significantly deteriorating position for Salarius's existing shareholders. The company's valuation has been halved in the merger terms, leading to massive dilution where legacy Salarius shareholders will own only 7.6% of the combined entity. Furthermore, Salarius's primary pipeline asset (IPR&D) is being immediately expensed, indicating it holds no future value for the combined company. While a capital raise is occurring, it primarily facilitates the merger under highly unfavorable terms for Salarius. This combination of severe dilution, asset write-off, and loss of control points to a strong negative outlook for current Salarius equity holders.

Keywords

Salarius Pharmaceuticals, Decoy Therapeutics, Merger Agreement, Reverse Merger, Biotechnology, Pharmaceuticals, SEC Filing, 8-K/A, Pro Forma Financials, Stock Split, Qualified Financing, Preferred Stock, Anti-Dilution, Nasdaq Compliance, IPR&D